Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).

Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, Stricker K, Chakraborty A, Tannenbaum S, Wright AM, Rordorf C.

Arthritis Res Ther. 2011 Feb 28;13(1):R34. doi: 10.1186/ar3266.

2.

Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.

Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, Kleinschmidt A.

Clin Vaccine Immunol. 2010 Dec;17(12):1952-7. doi: 10.1128/CVI.00175-10. Epub 2010 Oct 20.

3.

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.

Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T.

J Exp Med. 2009 May 11;206(5):1029-36. doi: 10.1084/jem.20082481. Epub 2009 Apr 13.

4.

Lower extremity sensory function in children with cerebral palsy.

McLaughlin JF, Felix SD, Nowbar S, Ferrel A, Bjornson K, Hays RM.

Pediatr Rehabil. 2005 Jan-Mar;8(1):45-52.

PMID:
15799135

Supplemental Content

Loading ...
Support Center